Arcellx reports Q3 EPS (81c), consensus (63c)

Reports Q3 revenue $15.0M, consensus $12.48M. As of September 30, Arcellx had cash, cash equivalents, and marketable securities of $482.7M. Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2026. “We are excited to have announced our upcoming oral presentation at ASH in December. As published in our recently released ASH abstract, median duration of response, progression free survival and overall survival were not reached in patients with a median follow-up of 22 months after infusion of CART-ddBCMA. Additionally, CART-ddBCMA continues to be well-tolerated at the time of the June 2 data cut with no observed delayed neurotoxicities or parkinsonian symptoms at the median follow-up of 22 months,” said Rami Elghandour, Arcellx’s Chairman and CEO. “We look forward to presenting data from this study with a median follow-up of 26.5 months for patients during an oral presentation at ASH. We continue to believe in the best-in-class potential for CART-ddBCMA for patients suffering from relapsed or refractory multiple myeloma based on the safety and efficacy profile. Additionally, we are excited to have resumed enrollment in our iMMagine-1 study as we continue to advance the program towards commercial availability.”